395 related articles for article (PubMed ID: 15489000)
1. Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids.
Iwai A; Fujii Y; Kawakami S; Takazawa R; Kageyama Y; Yoshida MA; Kihara K
Mol Cell Endocrinol; 2004 Oct; 226(1-2):11-7. PubMed ID: 15489000
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of COX-2, vascular endothelial growth factor and microvessel density in human renal cell carcinomas.
Hemmerlein B; Galuschka L; Putzer N; Zischkau S; Heuser M
Histopathology; 2004 Dec; 45(6):603-11. PubMed ID: 15569051
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells.
Yano A; Fujii Y; Iwai A; Kageyama Y; Kihara K
Clin Cancer Res; 2006 May; 12(10):3003-9. PubMed ID: 16707595
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
5. The growth-inhibitory effects of dexamethasone on renal cell carcinoma in vivo and in vitro.
Arai Y; Nonomura N; Nakai Y; Nishimura K; Oka D; Shiba M; Nakayama M; Takayama H; Mizutani Y; Miki T; Okuyama A
Cancer Invest; 2008 Feb; 26(1):35-40. PubMed ID: 18181043
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells.
Yano A; Fujii Y; Iwai A; Kawakami S; Kageyama Y; Kihara K
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6012-7. PubMed ID: 17062674
[TBL] [Abstract][Full Text] [Related]
7. VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma.
Rivet J; Mourah S; Murata H; Mounier N; Pisonero H; Mongiat-Artus P; Teillac P; Calvo F; Janin A; Dosquet C
Cancer; 2008 Jan; 112(2):433-42. PubMed ID: 18041056
[TBL] [Abstract][Full Text] [Related]
8. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile.
Baldewijns MM; Thijssen VL; Van den Eynden GG; Van Laere SJ; Bluekens AM; Roskams T; van Poppel H; De Bruïne AP; Griffioen AW; Vermeulen PB
Br J Cancer; 2007 Jun; 96(12):1888-95. PubMed ID: 17505508
[TBL] [Abstract][Full Text] [Related]
9. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.
Bran B; Bran G; Hörmann K; Riedel F
Int J Oncol; 2009 Jan; 34(1):255-61. PubMed ID: 19082496
[TBL] [Abstract][Full Text] [Related]
10. Expression of Ets-1 in human clear cell renal cell carcinomas: implications for angiogenesis.
Mikami S; Oya M; Mizuno R; Murai M; Mukai M; Okada Y
Cancer Sci; 2006 Sep; 97(9):875-82. PubMed ID: 16856880
[TBL] [Abstract][Full Text] [Related]
11. Dexamethasone induces neurodegeneration but also up-regulates vascular endothelial growth factor A in neonatal rat brains.
Feng Y; Rhodes PG; Liu H; Bhatt AJ
Neuroscience; 2009 Jan; 158(2):823-32. PubMed ID: 19007863
[TBL] [Abstract][Full Text] [Related]
12. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma.
Rini BI; Rathmell WK
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):741s-746s. PubMed ID: 17255303
[TBL] [Abstract][Full Text] [Related]
13. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.
Bates DO; Cui TG; Doughty JM; Winkler M; Sugiono M; Shields JD; Peat D; Gillatt D; Harper SJ
Cancer Res; 2002 Jul; 62(14):4123-31. PubMed ID: 12124351
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone coordinately regulates angiopoietin-1 and VEGF: a mechanism of glucocorticoid-induced stabilization of blood-brain barrier.
Kim H; Lee JM; Park JS; Jo SA; Kim YO; Kim CW; Jo I
Biochem Biophys Res Commun; 2008 Jul; 372(1):243-8. PubMed ID: 18485896
[TBL] [Abstract][Full Text] [Related]
15. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.
Ljungberg BJ; Jacobsen J; Rudolfsson SH; Lindh G; Grankvist K; Rasmuson T
BJU Int; 2006 Sep; 98(3):661-7. PubMed ID: 16925769
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of glucocorticoid-induced changes of Na(+), K(+)-ATPase in rat lens by a glucocorticoid receptor antagonist RU486.
Xie GL; Yan H; Lu ZF
Exp Eye Res; 2010 Oct; 91(4):544-9. PubMed ID: 20637751
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma.
Kausch I; Jiang H; Thode B; Doehn C; Krüger S; Jocham D
Eur Urol; 2005 May; 47(5):703-9. PubMed ID: 15826766
[TBL] [Abstract][Full Text] [Related]
18. 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway.
Matsuyama M; Yoshimura R; Mitsuhashi M; Tsuchida K; Takemoto Y; Kawahito Y; Sano H; Nakatani T
Oncol Rep; 2005 Jul; 14(1):73-9. PubMed ID: 15944770
[TBL] [Abstract][Full Text] [Related]
19. Endothelin-1 down-regulates the expression of vascular endothelial growth factor-A associated with osteoprogenitor proliferation and differentiation.
Veillette CJ; von Schroeder HP
Bone; 2004 Feb; 34(2):288-96. PubMed ID: 14962807
[TBL] [Abstract][Full Text] [Related]
20. Quantification by competitive quantitative RT-PCR of VEGF121 and VEGF165 in renal cell carcinoma.
Thelen P; Hemmerlein B; Kugler A; Seiler T; Ozisik R; Kallerhoff M; Ringert RH
Anticancer Res; 1999; 19(2C):1563-5. PubMed ID: 10365146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
